MedTrace Logo

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

NCT02886065 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-03-13

No results posted yet for this study

Summary

This research study is studying a targeted therapy as a possible treatment for Smoldering Multiple Myeloma.

The following intervention will be involved in this study:

* Lenalidomide
* Citarinostat (CC-96241)
* PVX-410

Conditions

  • Smoldering Multiple Myeloma

Interventions

DRUG

Hiltonol

Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration

DRUG

Citarinostat

Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.

DRUG

Lenalidomide

Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.

BIOLOGICAL

PVX-410

PVX-410 Biweekly (0.8 mg) via subcutaneous injection

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • OncoPep, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Noopur Raje, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-07
Primary Completion
2026-09-15
Completion
2026-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02886065 on ClinicalTrials.gov